Biomerica, Inc. revenue by segment BMRA

Annual Quarterly

Biomerica, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2026, which ended May 31, 2026 was Clinical Lab at $2.7 million, 61% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2027 Aug 31, 2026	FY 2026 May 31, 2026	FY 2025 May 31, 2025	FY 2024 May 31, 2024	FY 2023 May 31, 2023	FY 2022 May 31, 2022	FY 2021 May 31, 2021	FY 2020 May 31, 2020	FY 2019 May 31, 2019	FY 2018 May 31, 2018	FY 2017 May 31, 2017
Revenue	4	4	5	5	5	19	7	7	5	6	6
Clinical Lab	2 -15.2% share 57.2%	3 -14.1% share 61.4%	3 -1.7% share 59.9%	3 -2.2% share 59.8%	3 share 62.0%	—	—	—	—	—	—
Contract Manufacturing	1 -2.9% share 20.7%	1 -16.7% share 20.0%	1 +44.4% share 20.1%	1 +21.5% share 13.7%	1 share 11.4%	—	—	—	—	—	—
Over The Counte	1 -7.0% share 21.9%	1 -21.7% share 18.4%	1 -26.4% share 19.8%	1 +22.0% share 26.3%	1 share 21.9%	—	—	—	—	—	—
Physicians Office	0 -27.3% share 0.2%	0 -18.2% share 0.2%	0 -8.3% share 0.2%	0 -95.2% share 0.2%	0 share 4.7%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: BMRA (Nasdaq)
Fiscal year ends: May 31
Incorporated in: DE
Headquarters: Irvine, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 73290

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.